Good morning, and welcome to Permian Resources Conference Call to discuss its Fourth Quarter and Full Year 2025 Earnings. Today's call is being recorded. A replay of the call will be accessible until ...
As reported in December 2025, data from the aleniglipron clinical program included 36-week data from the core Phase 2b ACCESS study and the exploratory ACCESS II study, as well as interim data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results